July 15, 2022 01:42 PM EDTUpdated 04:23 PM
Pharma
Marketing

J&J ob­jects to Sanofi’s '#1 Doc­tor Rec­om­mend­ed' claims about heart­burn drug Zan­tac

Aayushi Pratap

News Reporter

French drug mak­er Sanofi has come un­der the scan­ner of the non­prof­it Na­tion­al Ad­ver­tis­ing Di­vi­sion (NAD) af­ter its arch-ri­val John­son & John­son com­plained about the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times